The role of hypertonic saline dextran in trauma resuscitation

Abstract

Modern trauma management has recognized the importance of using conservative fluid resuscitation regimes in order to prevent complications from fluid overload arising. Hypertonic/hyperoncotic fluids appear to provide an ideal means of facilitating this, requiring only small volumes to rapidly elevate blood pressure. Hypertonic saline dextran (HSD) was introduced in 1985 but its take up has been slow, a large part of this has been due to the lack of human trials and concerns about complications. The current evidence has been reviewed and it is clear that HSD is an efficient means of correcting hypotension, doing so mainly by the mobilizing endogenous water. It is becoming apparent that early administration has the potential to modulate the inflammatory cascade in patients at risk of developing adult respiratory distress syndrome (ARDS) and multiorgan failure. This is reflected in the handful of human trials that show a trend towards increased survival (particularly for head injuries) and a possible reduction in ARDS. The side effect profile appears to be good, even in the presence of dehydration or penetrating trauma. Published human trials have methodological problems and lack of power of study this has led to a reliance on animal studies. Clearly there is great potential, but before large-scale prehospital usage can be justified further well-conducted randomized human trials are needed.